MedTrace Logo

Single-Dose Study of MT203

NCT02354599 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate safety, pharmacokinetics and pharmacodynamics of single subcutaneous injection of MT203 in healthy adult Japanese and Caucasian male participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

MT203 80 mg or matching Placebo

MT203 80 mg or matching placebo injection

DRUG

MT203 150mg or matching Placebo

MT203 150mg or matching placebo injection

DRUG

MT203 300 mg or matching placebo

MT203 300 mg or matching placebo injection

Sponsors & Collaborators

Principal Investigators

  • Senior Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02354599 on ClinicalTrials.gov